Zevra Therapeutics (ZVRA) Change in Receivables (2019 - 2026)

Zevra Therapeutics has reported Change in Receivables for 8 years, with the latest figure at -$6.9 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables fell 426.85% year-over-year to -$6.9 million; the trailing twelve-month figure through Mar 2026 stood at $3.0 million (down 30.91% YoY), and the FY2025 full-year result was $12.0 million, up 274.39% from the prior year.
• Change in Receivables for Q1 2026 stood at -$6.9 million, down from $6.4 million in the prior quarter.
• The five-year high for Change in Receivables was $7.4 million in Q4 2023, with the low at -$9.1 million in Q1 2024.
• Historically, Change in Receivables has averaged $827588.2 across 5 years, with a median of $1.8 million in 2022.
• Annual changes were most pronounced in 2022 — Change in Receivables surged 2436.26% — and 2024, when it sank 1801.89%.
• Zevra Therapeutics' Change in Receivables stood at $2.1 million in 2022, then soared by 250.42% to $7.4 million in 2023, then slumped by 63.5% to $2.7 million in 2024, then surged by 134.17% to $6.4 million in 2025, then tumbled by 208.21% to -$6.9 million in 2026.
• The last three Change in Receivables figures came in at -$6.9 million (Q1 2026), $6.4 million (Q4 2025), and -$1.4 million (Q3 2025), per Business Quant data.